FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

DIVISLAB

3,151
-85.6 (-2.64%)
Updated 03:29 23/09 IST

DIVISLAB Buy or Sell - FrontPage Forums

0 Users have submitted 0 trade ideas of Rs. 0 for DIVISLAB
Disclaimer
0% Bullish
0% Bearish

DIVISLAB Buy or Sell - Brokerage Reports

No. of reports in last year
3
No. of analysts
2
Average Consensus Forecast
2471
Consensus Potential
-33.54%
See DIVISLAB Share Price Targets >>

DIVISLAB Ratings

Long term DIVISLAB rating by FrontPage users
4/5 (2 Ratings)
Find answers to all your questions on live DIVISLAB message board: Is DIVISLAB buy or sell? Should I buy DIVISLAB shares? Why are DIVISLAB shares falling? Should I invest in DIVISLAB stock?

  1. Home
  2. DIVISLAB Forum

DIVISLAB Share Price Discussion


Type
Sell
Instrument
DIVISLAB
Entry Price
₹3,200
Price@Trade
₹3,190
Target Price
₹3,129.6
Stop Price
₹3,241.65
Valid Till
Sep 23, 2020 3:20 AM
Margin
₹99,200 approx for 31 Qty
Status
Waiting for entry
Like
Reply
M
Reputation: -10,440 • Yesterday 5:42 AM

Type
Buy
Instrument
NIFTY 29OCT20 FUT
Entry Price
₹11,172
Price@Trade
₹11,172
Target Price
₹11,500
Stop Price
₹11,000
Valid Till
Oct 29, 2020 3:20 AM
Margin
₹139,835.08 approx for 75 Qty
Status
Active
Like
Reply

Type
Buy
Instrument
BANKNIFTY 19NOV20 19500 PE
Entry Price
₹4.8
Price@Trade
₹0
Target Price
₹10
Stop Price
₹0
Valid Till
Sep 23, 2020 3:20 AM
Margin
₹4,800 approx for 1000 Qty
Status
Exited before entry
Like
Reply (1)
See all replies
Vishal A @vishala-HkmmYD9cU
Yesterday 5:42 AM

Update
Exited before entry
Price @ Update
₹0

Type
Sell
Instrument
DIVISLAB
Entry Price
₹3,190
Price@Trade
₹3,190
Target Price
₹3,081.5
Stop Price
₹3,256.1
Valid Till
Sep 23, 2020 3:20 AM
Margin
₹98,890 approx for 31 Qty
Status
Active
Like
Reply
R
Reputation: -39,576 • Yesterday 5:41 AM

Type
Buy
Instrument
BANKNIFTY 01OCT20 22000 CE
Entry Price
₹133.55
Price@Trade
₹133.55
Target Price
₹1,000
Stop Price
₹50
Valid Till
Oct 1, 2020 3:20 AM
Margin
₹200,325 approx for 1500 Qty
Status
Active
Like
Reply

Type
Sell
Instrument
BANKNIFTY 24SEP20 20800 CE
Entry Price
₹421.4
Price@Trade
₹421.4
Target Price
₹30
Stop Price
₹800
Valid Till
Sep 24, 2020 3:20 AM
Margin
₹252,111.95 approx for 50 Qty
Status
Active
Like
Reply

Type
Sell
Instrument
GRANULES
Entry Price
₹360.3
Price@Trade
₹360.3
Target Price
₹338.45
Stop Price
₹372.05
Valid Till
Sep 23, 2020 3:20 AM
Margin
₹99,803.1 approx for 277 Qty
Status
Active
Like
Reply

Type
Buy
Instrument
BANKNIFTY 24SEP20 21200 CE
Entry Price
₹160
Price@Trade
₹164.1
Target Price
₹300
Stop Price
₹130
Valid Till
Sep 23, 2020 3:20 AM
Margin
₹80,000 approx for 500 Qty
Status
Waiting for entry
Like
Reply
K
Reputation: -2,063 • Yesterday 5:40 AM

Type
Buy
Instrument
BHARTIARTL SEP20 FUT
Entry Price
₹435.5
Price@Trade
₹435.5
Target Price
₹470
Stop Price
₹434.35
Valid Till
Sep 23, 2020 3:20 AM
Margin
₹496,408.82 approx for 1851 Qty
Status
Exited
Exit Price
₹435.45
Net P&L
-₹92.55 (-0.02%)
Like
Reply (1)
See all replies
kiransai77 @kiransai77
Yesterday 5:42 AM

Update
Exited
Exit Price
₹435.45
Net P&L
-₹92.55 (-0.02%)
R
Reputation: 354 • Yesterday 5:40 AM

GOLD BUY 49750-700
TARGET 49950
TARGET 50150
Like
Reply
O
Reputation: -367 • Yesterday 5:40 AM

Type
Sell
Instrument
BANKNIFTY 24SEP20 FUT
Entry Price
₹21,150
Price@Trade
₹21,161.95
Target Price
₹20,950
Stop Price
₹21,300
Valid Till
Sep 23, 2020 3:20 AM
Margin
₹929,875.8 approx for 200 Qty
Status
Waiting for entry
Like
Reply

Type
Sell
Instrument
RELIANCE
Entry Price
₹2,242
Price@Trade
₹2,242
Target Price
₹2,178.45
Stop Price
₹2,275.8
Valid Till
Sep 23, 2020 3:20 AM
Margin
₹98,648 approx for 44 Qty
Status
Active
Like
Reply

Type
Sell
Instrument
IDEA
Entry Price
₹9.6
Price@Trade
₹9.55
Target Price
₹8.5
Stop Price
₹10.15
Valid Till
Sep 23, 2020 3:20 AM
Margin
₹99,993.6 approx for 10416 Qty
Status
Active
Like
Reply (1)
See all replies
TrackerBot @trackerbot
Yesterday 5:40 AM

Update
Trade Entered
Entry Price
₹9.6

Type
Sell
Instrument
GRANULES
Entry Price
₹360.35
Price@Trade
₹360.35
Target Price
₹350
Stop Price
₹370
Valid Till
Sep 23, 2020 3:20 AM
Margin
₹180,175 approx for 500 Qty
Status
Active
Like
Reply

Type
Buy
Instrument
BAJAJ-AUTO SEP20 FUT
Entry Price
₹2,998.75
Price@Trade
₹2,998.75
Target Price
₹3,019
Stop Price
₹2,993.5
Valid Till
Sep 23, 2020 3:20 AM
Margin
₹683,080.75 approx for 500 Qty
Status
Active
Like
Reply
S
Reputation: -4,856 • Yesterday 5:39 AM

Type
Buy
Instrument
NIFTY 24SEP20 11200 PE
Entry Price
₹81.8
Price@Trade
₹81.8
Target Price
₹100
Stop Price
₹78
Valid Till
Sep 24, 2020 3:20 AM
Margin
₹613,500 approx for 7500 Qty
Status
Exited
Exit Price
₹84.5
Net P&L
+₹20,250 (+3.3%)
Like
Reply (1)
See all replies
Shantanu @shantanudethe
Yesterday 5:40 AM

Update
Exited
Exit Price
₹84.5
Net P&L
+₹20,250 (+3.3%)

Type
Buy
Instrument
BANKNIFTY 24SEP20 19500 PE
Entry Price
₹4.7
Price@Trade
₹4.9
Target Price
₹10
Stop Price
₹0
Valid Till
Sep 23, 2020 3:20 AM
Margin
₹117.5 approx for 25 Qty
Status
Exited before entry
Like
Reply (1)
See all replies
Vishal A @vishala-HkmmYD9cU
Yesterday 5:39 AM

Update
Exited before entry
Price @ Update
₹4.95

Type
Sell
Instrument
RELIANCE
Entry Price
₹2,243.8
Price@Trade
₹2,243.8
Target Price
₹2,177.6
Stop Price
₹2,274.95
Valid Till
Sep 23, 2020 3:20 AM
Margin
₹98,727.2 approx for 44 Qty
Status
Active
Like
Reply

Type
Buy
Instrument
BANKNIFTY 24SEP20 21200 CE
Entry Price
₹171.75
Price@Trade
₹171.75
Target Price
₹300
Stop Price
₹120
Valid Till
Sep 24, 2020 3:20 AM
Margin
₹34,350 approx for 200 Qty
Status
Active
Like
Reply
J
Reputation: -8,899 • Yesterday 5:38 AM

Type
Buy
Instrument
BANKNIFTY 24SEP20 21500 CE
Entry Price
₹64.2
Price@Trade
₹64.2
Target Price
₹80
Stop Price
₹52
Valid Till
Sep 24, 2020 3:20 AM
Margin
₹128,400 approx for 2000 Qty
Status
Active
Like
Reply
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • DIVISLAB - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization45,211.44
    Enterprise Value45,212.24
    Price to Earnings33.24
    Price to Book Value6.48
    Return on Capital Employed0.2
    Return on Equity0.15
    Face Value2
    Dividend Yield0.01
  • DIVISLAB - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    12-Aug-20Karvy Stock BrokingSell2,912
    8-Jun-20Karvy Stock BrokingSell2,071
    20-Feb-20SharekhanBuy2,430
    19-Aug-19SharekhanBuy1,800
    12-Aug-19Karvy Stock BrokingHold1,744
    DIVISLAB Brokerage Price Target
  • DIVISLAB Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Sep 233253.753290.431293147.55
    Sep 213350.953374.253120.053158.8
    Sep 183230338932283344.4
    Sep 173244.053264.232003211.15
    Sep 163181.1327431793244.35
  • DIVISLAB Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹3,207.82
    30 Day Moving Average₹3,194.4
    50 Day Moving Average₹2,905.59
    100 Day Moving Average₹2,613.59
    200 Day Moving Average₹2,306.79
  • DIVISLAB - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue3,8164,023.47-0.05
    Operating Profit1,2521,438.85-0.13
    Profit Before Tax1,2191,388.23-0.12
    Net Income8701,053.27-0.17
  • DIVISLAB - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds6,9735,9600.17
    Total Liabilities1,0678610.24
    Total Assets8,0406,8210.18
  • DIVISLAB - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity7651,148.05-0.33
    Cash from Investing Activity-476-1,134.08-0.58
    Cash from Financing Activity-314-9.3132.73
    Net Cash Flow-254.66-6.36
  • DIVISLAB - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.130.17
    Return on Equity0.150.19
    Return on Capital Employed0.20.26
  • DIVISLAB - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.24
    3 Year CAGR Growth in Operating Profit0.08
    3 Year CAGR Growth in EBIDTA0.13
    3 Year CAGR Growth in Net Income0.03
    3 Yr CAGR Growth - Diluted EPS-0.49
  • DIVISLAB - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.79
    5 Year CAGR Growth in Operating Profit0.52
    5 Year CAGR Growth in EBIDTA0.57
    5 Year CAGR Growth in Net Income0.42
    3 Yr CAGR Growth - Diluted EPS-0.29
  • DIVISLAB - Recent News

    keyboard_arrow_down
    NewsBot
    Aug 20 2:28 AM
    SBI Life, Divis Labs to replace Bharti Infratel, ZEE in Nifty50
    Moneycontrol
    NewsBot
    Aug 11 12:43 PM
    Buy Divi’s Laboratories; target of Rs 3350: Motilal Oswal
    Moneycontrol
    NewsBot
    Aug 11 12:43 PM
    Buy Divis Laboratories; target of Rs 3400: Sharekhan
    Moneycontrol
    NewsBot
    Aug 10 6:48 AM
    Buy Divi's Laboratories; target of Rs 3260: ICICI Direct
    Moneycontrol
    NewsBot
    Aug 10 3:48 AM
    Divis Labs shares rally 12% as Q1 profit spikes 81%; HSBC raises target to Rs 2,755
    Moneycontrol
    NewsBot
    Aug 10 3:43 AM
    Divis Labs Standalone June 2020 Net Sales at Rs 1,709.96 crore, up 50.01% Y-o-Y
    Moneycontrol
    NewsBot
    Aug 10 3:33 AM
    Divis Labs Consolidated June 2020 Net Sales at Rs 1,730.47 crore, up 48.81% Y-o-Y
    Moneycontrol
    NewsBot
    Aug 8 7:48 AM
    Divi's Laboratories Q1 profit up 81% at Rs 492 crore
    Moneycontrol
    NewsBot
    Jul 19 8:38 AM
    Divi's Lab CFO Kishore Babu goes on three-month leave after allegations of insider trading
    Moneycontrol
    NewsBot
    Jul 19 1:43 AM
    IT space looking attractive! TCS and Tech Mahindra top long-term buys: Reliance Securities
    Moneycontrol
  • DIVISLAB - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Cadila Healthcare Ltd. NSE: CADILAHC ...
    Apollo Hospitals Enterprise Ltd. NSE:...
  • DIVISLAB - More Information

    keyboard_arrow_down

    Divi's Laboratories Ltd:
    Divi's Laboratories Limited is incorporated back in 1990 and headquartered in Hyderabad, Telangana, India. This company, at its initial stage of the foundation, was named as Divi's Research Centre and later on in 1994 was changed to Divi's Laboratories Limited. This company is responsible for manufacturing and selling APIs or active pharmaceutical ingredients along with intermediates for generics. This is carried on in India, other parts of Asia, US, Europe and several other parts of the world.
    It offers the different unit for building compounds like several carotenoids inclusive of beta-carotene, astaxanthin, canthaxanthin, lycopene, and apocarotenol. Other than this it also offers groups for building protects amino acids like FMOC, BCZ and BOC as well as for chiral ligands and peptide and nucleotides.
    Apart from this, it also customizes the synthesis of several active pharmaceutical ingredients along with advanced forms of discovered compounds for other pharmaceutical companies. It also offers full-time contract-based research on development processes to identify new compounds.
    Company Information:
    Between the years 1991-1993, Divi's developed multiple bulk actives and other intermediates products for several other manufacturing companies. It received its ISO-9002 certification with compliance to SGS-Yarsley belonging to the UK, back in 1997. With the following two years, in 1999, the company received a Certificate of Suitability from the European Directorate for the production of Naproxen.
    For the company's system of occupational health and safety management, it received the OHSAS-18001 certificate. It was given to them by BVQI from London in 2001. In the year 2002, Divi's set up their Unit number II, a manufacturing facility in Chippada. In the following year in 2003, the company inaugurated a new research centre in Vizag, named DRC-Vizag. This was built for fundamental research in specific core segments.
    In the year 2004, Rs 3035.21 lakh was invested by Divi's for adding machines to both of their units in Unit-I (Choutuppal) and Unit-II (Chippada), and this was accounted for in their capital expenditure. In 2006, it received an approval letter from the Ministry of Commerce in India. This was for setting up a Special Economic Zone for multiple pharma based ingredients at Chippada, Vizag which led the company to invest Rs 200 crore.
    During the year 2008-09, the company's portfolio added a total of 9 products. Four of these nine products consisted of generic APIs, and the rest belonged to intermediates and custom synthesis of APIs. Another seven products were added to the company portfolio in 2009-2010. Out of these seven products, 2 were generic APIs along with intermediates, while the rests were intermediates and custom synthesis APIs. During the year 2012-13, the company went on to add another nine products out of which three of these were generic APIs along with intermediates, and the rest six were custom synthesis APIs and intermediates.
    On 19 February 2016, the company went through an inspection by US-FDA for its second unit in Chapada, Bhemunipatam near Vizag and was this event was successful which happened without any observation. In 2017, on 18 November, the company announced that it had received EIR (Establishment Inspection Report) from FDA (US) for their second unit in Vizag. On 16 May 2018, Divi's Laboratories stated that their Unit-I in Telangana was under the inspection of the US-FDA starting from 14 May 2018 to 16 May 2018. The review conducted was a cGMP general inspection done by the FDA.
    The company is one of the biggest pharmaceutical companies in the country, which currently has a portfolio of 120 products. It has presently products belonging to multiple therapeutic aspects. It has a total of four manufacturing units with a developing market presence in several countries. Their first facility is located in Yadadri Bhuvanagiri District; Telangana consists of 11 blocks for multipurpose production along with finishes product spaces for APIs.
    How Divi’s Laboratories, is categorised as a Pharmaceutical and Health care Sector, and Pharmaceutical Industry :
    The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
    Divi's Laboratories is categorized under the Pharmaceutical and Health care sector and Pharmaceutical Industry. Healthcare sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more.
    The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
    Divi’s Laboratories, Competitors and Sector Peers:
    Abbott India Ltd. ABBIND
    Alembic Ltd. ALELTD
    Alembic Pharmaceuticals Ltd. ALEPHA
    Alkem Laboratories Ltd. ALKLAB
    Alpa Laboratories Ltd. ALPLAB
    Ambalal Sarabhai Enterprises Ltd. AMBSAR
    AstraZeneca Pharma India Ltd. ASTZEN
    Bafna Pharmaceuticals Ltd. BAFPHA
    Bajaj Healthcare Ltd. BAJHEA
    Biocon Ltd. BIOLTD
    Cian Healthcare Ltd.
    Cipla Ltd. CIPLTD
    Concord Drugs Ltd. CONDRU
    Dishman Pharmaceuticals & Chemicals Ltd.[Merged] DISPHA
    Divi's Laboratories Ltd. DIVIL
    Dr. Reddy's Laboratories Ltd. DR
    GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
    Glenmark Pharmaceuticals Ltd. GLEPHL
    IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
    Lincoln Pharmaceuticals Ltd. LINPHA
    Lupin Ltd. LUPLTD
    Madhuveer Com 18 Network Ltd. TOHPHA
    Mahavir Advanced Remedies Ltd. INDAME
    Makers Laboratories Ltd. MAKLAB
    Natco Pharma Ltd. NATPHA
    Natural Capsules Ltd. NATCAP
    Ranbaxy Laboratories Ltd. RANLAB
    Sanofi India Ltd. AVEPHA
    Sharon Bio-Medicine Ltd. SHAPHA
    Sun Pharmaceutical Industries Ltd. SUN28
    Zenith Healthcare Ltd. ZENHEA
    Zyden Gentec Ltd. ZYDGEN
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020